Next Monday, November 19, Vall d’Hebron will hold a seminar focused on Lysosomal Rare Disorders: Focus on Fabry Disease. The seminar is part of the Rare Diseases Program at the Vall d’Hebron Campus, in collaboration with the European...
Read more
Dr. Joan Genescà, head of the Liver Diseases research group and Dr. María Martell, group researcher and head of the Advanced Liver Disease laboratory, from the Liver Diseases group at VHIR, have received funding for a European research project in...
Read more
The European Commission, upon proposal from the European Medicines Agency (EMA), has designated Gefitinib as an orphan drug for Fanconi anemia. This orally administered product is currently indicated for the treatment of lung cancer. The studies...
Read more
Pre-doctoral researcher Mónica Vall, from the research group in Renal Physiopathology – CIBBIM Nanomedicine led by Dr. Anna Meseguer, won the prize for the best poster – short communication from the XLIII National Congress of...
Read more
Recently, Dr. J Raúl Herance, co-head of the Molecular Medical Imaging group at the Vall d’Hebron Research Institute (VHIR) has been elected to the position of Co-chair of the Spanish Group of the European Molecular Imaging Society. It will...
Read more
For the first time, the Vall d’Hebron Campus has a FET Innovation (Future and Emerging Technologies) project that has been awarded within the Horitzo 2020 program to the CIBBIM-Nanomedicine. Drug Delivery and Targeting research group...
Read more
The CIBER-BBN-CIBBIM group, led by Dr. Simó Schwartz, coordinating NANBIOSIS U20. In Vivo Experimental Platform has been granted a FET Innovation project (Future and Emerging Technologies) within the Horizon 2020 program. The EVO-NANO project...
Read more
The Fabry International Network (FIN) association has established the month of April as the “month of Fabry” to raise awareness and educate about this disease, a rare, progressive and with multi-organ involvement pathology. Fabry...
Read more
In the coming days the Precision Nanomedicine journal will see the light, in its online version that is already being finalised. Dr. Simón Schwartz Jr, director of CIBBIM-Nanomedicine, is one of only two Spanish researchers who are part of the...
Read more
One of the main problems that nanomedicine must face is the improvement of drugs transport and release systems to the correct place of action. And in particular, to take nucleic acids to the right target cells. The team led by Dr. Simó Schwartz...
Read more
This January, the Area of Functional Validation & Preclinical Research (FVPR) of CIBBIM-Nanomedicine has obtained the ISO 9001:2008 certification of Quality Management Systems for functional validation, preclinical development and/or...
Read more
Asdent (Association of Dent Disease) has delivered 114,978.55 euros to the Vall d’Hebron Research Institute (VHIR) to continue researching this disease. The pathology of Dent is a hereditary minority disease linked to the X chromosome and...
Read more
